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Abstract
I In nt tr ro od du uc ct ti io on n: :   To investigate the hypothesis that atorvastatin decreases blood
pressure (BP) values and improves endothelial function assessed by flow-medi-
ated dilation (FMD) in normolipidaemic hypertensive patients.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   Fifty-six hypertensive patients were randomized in 
a 2 : 1 proportion to atorvastatin (80 mg/day/3 months; group A; n = 39) or pre-
vious standard anti-hypertensive therapy (group B), which means the patients
were treated with angiotensin-converting enzyme inhibitors, diuretics, ʲ-block-
ers, calcium antagonists and angiotensin receptor blockers. The study had
a crossover design: after 3 months, both groups were changed (group A* stopped
and group B* started atorvastatin treatment). Nitric oxide (NO), total antioxi-
dant status (TAS), endothelin-1 (ET-1), and peroxide concentrations as well as
FMD were measured before, after 3 and after 6 months of treatment. Atorvas-
tatin added to existing treatment decreased BP in both groups. 
R Re es su ul lt ts s: :   Flow-mediated dilation improved in both statin-treated groups, but
only significantly in group B* (from 11.9 ±8.3% to 22.1 ±9.0%; p < 0.05). In
patients with FMD improvement, there was a greater BP reduction. After treat-
ment discontinuation, FMD significantly decreased (from 19.6 ±12.6% to 13.0
±10.5%; p < 0.05), which was consistent with BP increase. Changes in FMD were
not significantly related to the increase in NO and TAS concentrations and
decrease in ET-1 and peroxides measurements.  
C Co on nc cl lu us si io on ns s: :   The hypotensive effect of atorvastatin is associated with FMD
improvement in normolipidaemic, hypertensive patients. Although this could
be related to changes in oxidative stress and endothelial function, this was not
demonstrated in this study and warrants further investigation.
K Ke ey y   w wo or rd ds s: :   arterial hypertension, endothelin-1, flow-mediated dilation, nitric oxide,
peroxides, total antioxidant status.
Introduction
Essential arterial hypertension and hyperlipidaemia are powerful risk
factors of cardiovascular disease. Endothelial dysfunction is a leading cause
of early development and preservation of arterial hypertension [1]. Endothe-
lial function can be assessed using ultrasound methods to observe the
arterial flow-mediated dilation (FMD). It is also possible to assess bio-
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markers of endothelial function, of which nitric
oxide (NO) and endothelin-1 (ET-1) play a crucial
role. The increase in ET-1, as well as NO defective
endothelial release, is common in hypertensive
patients [1, 2]. Moreover, it is thought that high
blood pressure values are associated with a loss of
balance between the status of oxidative stress and
the level of antioxidants [3]. 
Apart from lowering cholesterol, statins demon-
strate other biological actions, including anti-inflam-
matory effects and improved endothelial function.
Current data indicate that statins could have an
extensive range of indications [4].
Statins interact with blood pressure control in
different populations of hypertensive patients [5].
However, the influence of statin therapy on perox-
ide concentrations as well as total antioxidant sta-
tus  in  normolipidaemic  hypertensive  patients
remains unclear.
This study sought to investigate, in a crossover
design, the improvement of endothelial dysfunc-
tion in normolipidaemic patients with hypertension
under treatment, before and after atorvastatin
treatment, and to determine whether the alteration
of biomarkers assessing endothelial function (NO
and ET-1), oxidative stress (measured by Oxystat),
or total antioxidative status could be responsible
for that effect.
Material and methods
S St tu ud dy y   p po op pu ul la at ti io on n
Among 92 patients referred to our outpatient
clinic with previously diagnosed and treated essen-
tial arterial hypertension, we studied 56 (32 males;
aged 44 to 64 years) non-smoking, normolipidaemic
ones. The mean time of a history of arterial hyper-
tension was 5 ±3.2 years. Patients were randomized
in an open-label manner in a 2 : 1 proportion to ator-
vastatin (80 mg/day/3 months; group A, n = 39), or
to the standard, previous therapy (group B, n = 17),
which means that these patients were treated with
standard  anti-hypertensive  agents  including
angiotensin-converting enzyme inhibitors (ACE-I),
diuretics, ʲ-blockers (BB), calcium antagonists (CA)
and angiotensin receptor blockers (ARB). The pro-
portion of anti-hypertensive agents was similar
between groups. The exact method of randomiza-
tion and the percentage of antihypertensive agents
are described elsewhere [6]. The mean value of total
cholesterol for the whole group was 185.2 mg/dl
(SD ±38.8). Atorvastatin significantly reduced total
cholesterol (TC), low density lipoprotein (LDL) and
triglyceride (TG) concentrations [6]. The activities
of alanine and aspartate aminotransferases did not
significantly change after atorvastatin treatment.
The study was done in a crossover design – after
3 months, the groups were changed: group A* and
B*. With this type of study, every patient serves as
his or her own control. Blood pressure were meas-
ured using a 24-h ambulatory blood pressure meas-
urement device (ABPM, Tracker Reynolds NIBP2,
Reynolds  Medical,  Hertford,  UK)  as  previously
described [6]. Basic mean values for systolic and
diastolic blood pressures were similar in groups
A and B: systolic blood pressure 129 ±11 mmHg vs.
129.5  ±13 mmHg  and  diastolic  blood  pressure 
76 ±9 mmHg vs. 74 ±7.6 mmHg (p = NS). 
The study design complied with the Helsinki
Declaration of 1975 (revised in 1996), and it was
approved by the local institutional committee on
human research (Institutional Review Board – Local
Bioethics Committee of Bialystok Medical Univer-
sity). Informed consent of all participants covered
by the study was obtained.
Endothelium-dependent FMD was estimated fol-
lowing the instructions given by Corretti and asso-
ciates [7]. Flow-mediated dilation was determined
in both groups at baseline, after 3 months (before
crossover), and at the end of the study (3 months
after crossover). All participants fasted for 12 h and
avoided exercise for 4 to 6 h before FMD examina-
tion. 
The brachial artery diameter was measured 6 cm
above the antecubital space using a high-resolu-
tion ultrasound 7.5-MHz linear array transducer
(Toshiba SSA-140A). Baseline imaging was followed
by 5-min occlusion of arterial flow, achieved by
inflating a pneumatic cuff above the antecubital
fossa (upper arm occlusion to at least 50 mmHg
above systolic blood pressure to occlude arterial
flow).  After  deflating  the  pneumatic  cuff,  the
brachial artery was imaged continuously for 3 min
(reactive hyperaemia and endothelium-dependent
dilation). The internal diameter (measured in mm)
was defined as the distance between the intima-
lumen interface of the near wall and the intima-
lumen interface of the far wall, and was assessed
during late-diastole corresponding to the R wave of
the electrocardiogram (ECG) trace. The maximum
diameter was taken into consideration. Flow medi-
ated dilation was expressed as percentage change
from rest [× 100 (brachial artery diameter at peak
hyperaemia – diameter at rest)/diameter at rest].
Measurements were performed in a blinded man-
ner, without knowledge of the patient’s group
assignment.
B Bl lo oo od d   s sa am mp pl li in ng g   a an nd d   b bi io oc ch he em mi ic ca al l   
m me ea as su ur re em me en nt ts s   
Venous blood samples were obtained from fast-
ing patients between 8:00 am and 10:00 am. The
patients were lying comfortably in the supine posi-
tion for 15 min. After that time, an antecubital vein
of the non-dominant forearm was cannulated, and
after another 20 min, venous blood samples forArch Med Sci 6, December / 2011 957
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total antioxidant status, peroxides, NO, and ET-1
assays were collected into tubes with the clotting
activation system (tubes for ET-1 were put on ice
immediately after collection). All samples were cen-
trifuged within 2 h after drawing and stored at 
–80°C until assayed. 
Serum concentration of total antioxidant status
was assayed using an enzymatic method with per-
oxidase by commercially available RANDOX total
antioxidant status kits (Randox, Ardmore, United
Kingdom) according to the manufacturer’s instruc-
tions. This method has been described previously [8]. 
Plasma concentrations of peroxides were meas-
ured using Oxystat colorimetric assay kits (Bio-
medica, Wien, Austria). The results show a direct
correlation between free radicals and circulating
biological peroxides, and thus allow characteriza-
tion of the oxidative status in biological samples.
The peroxide concentration is determined by the
reaction of the biological peroxides with peroxidase
and  subsequent  colour-reaction  using  tetram-
ethylbenzidine as a substrate. After addition of
a stop solution, the coloured liquid is measured
photometrically at 450 nm [9]. The intra-assay coef-
ficient of variation is referred to by the manufac-
turer of assay kits as 3.1% at peroxide mean con-
centration of 221 µmol/l, SD = 6.9 µmol/l. 
Serum levels of NO were measured using col-
orimetric total NO/nitrite/nitrate assay kits (R&D
Systems, Abingdon, England) [6]. The intra-assay
CV% is reported by the manufacturer of assay kits
as 2.5% at NO mean concentration of 30 µmol, 
SD = 0.76 U/l. 
Serum concentrations of ET-1 were measured
using enzyme-linked immunosorbent assay (ELISA)
kits (Biomedica, Wien, Austria). The intra-assay coef-
ficient of variation is referred to by the manufac-
turer of assay kits as 4% at ET-1 mean concentra-
tion of 2.02 fmol/ml, SD = 0.08. 
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s      
Results are expressed as means ± standard devi-
ation (SD) or 95% confidence interval, CI (variables
with the normal distribution) or n, percentage,
depending on the type of variables. Particular clini-
cal and biochemical parameters were compared
using ANOVA for repeated measures for principal
factors or recurrent measurements and a ˇ2 test. All
analyses were done using Statistica 9.1 PL. Value of
p below 0.05 was considered statistically significant. 
Results
Baseline clinical and biochemical characteristics
of  the  study  patients  are  shown  in  Table  I. 
Atorvastatin, added to the existing therapy for 
3 months, decreased blood pressure values in both
groups – in group A: systolic blood pressure –
5.7 mm Hg (95% confidence interval (CI) –4.1 mmHg
to –7.2 mmHg) and diastolic blood pressure –
3.9 mmHg (95% CI –2.7 mmHg to –5.0 mmHg), and
in group B*: systolic blood pressure –1.23 mmHg
(95% CI –6.93 to 4.46) and diastolic blood pressure
–2.0 mmHg (95% CI –5.46 to 1.46) (Figure 1). 
Flow-mediated  dilation  showed  significant
improvement in group B* (from 11.9 ±8.3% to 22.1
±9.0%; p < 0.05), but was not significant in group A
(from 18.7 ±8.9% to 19.6 ±12.6%; p = 0.7) (Figure 2).
However, in group A* (after crossover), systolic blood
pressure values significantly increased (p = 0.02) 
and FMD significantly decreased (from 19.6 ±12.6%
to 13.0 ±10.5%; p < 0.05) (Figures 1 and 2). 
In an ANOVA test, in patients with FMD improve-
ment  after  atorvastatin  treatment,  there  was
a trend to a greater blood pressure reduction – 
in group A (before crossover): systolic blood pres-
sure –7.2 mmHg (95% CI –10.75 to –3.62) and dias-
tolic blood pressure –4.8 mmHg (95% CI –6.85 to –
2.78) and a significant blood pressure reduction in
group B* (after crossover): systolic blood pressure
–3.1 mmHg (95% CI –9.91 to –3.75) and diastolic
blood pressure –2.4 mmHg (95% CI –6.68 to –1.91)
(Figure 3).
In group A, FMD improvement and aggravation
were not associated with significant changes (the
increase) in total antioxidant status concentrations:
mean 0.04 mmol/l (95% CI –0.91 to 0.18) and 0.02
mmol/l (95% CI –0.10 to 0.13) (Figure 4). Also, in
that group of patients, neither FMD improvement
nor impairment was associated with significant
changes in Oxystat (decrease: mean –64.1 µmol/l
(95%  CI  –183.9  to  55.7)  and  increase:  mean 
9.6 µmol/l (95% CI –103.8 to 123.0), respectively) 
(Figure 4). 
In group B* (receiving statin after crossover),
patients with FMD improvement had a trend to an
increase  in  NO  concentrations  (mean  2.7  IU/l 
P Pa ar ra am me et te er r G Gr ro ou up p   A A G Gr ro ou up p   B B V Va al lu ue e   
( (n n = =   3 39 9) ) ( (n n = =   1 17 7) ) o of f   p p
Age, mean ± SD  52.5 ±14.7 47.9 ±18.1 0.31
[years]
Sex, males [%] 43 53 0.49
TAS, mean ± SD  1.5 ±0.2 1.4 ±0.3 0.9
[mmol/l]
Peroxides,  326.8 ±194.3 249.1 ±139.8 0.05
mean ± SD [µmol/l] 
NO, mean ± SD  22.6 ±14.2 39.9 ±29.5 0.4
[IU/l] 
ET-1, mean ± SD  1.32 ±2.2 0.5 ±0.2 0.14
[fmol/ml] 
T Ta ab bl le e   I I. . Baseline clinical and biochemical character-
istics of study patients
SD – standard deviation, TAS – total antioxidant status, NO – nitric
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(95% CI –5.34 to 10.91)) and decrease in ET-1 values
(mean –0.2 fmol/ml [95% CI –0.41 to 0.06]) (Figure 5).
In patients without FMD improvement, NO de  -
creased (mean –17.0 IU/l [95% CI –46.30 to 12.26]),
whereas  ET-1  increased  (mean  0.02  fmol/ml 
(95% CI –0.82 to 0.86)) (Figure 5). However, these
trends were not significant.
Discussion
The results of this study suggest that the hy  -
potensive effect of atorvastatin is related to FMD
improvement in a selected group of hypertensive
patients. Two actions could be responsible for this
antihypertensive effect: FMD variation probably
depends on concentration changes in oxidative
stress/antioxidants as well as changes in biomark-
ers of endothelial function (NO, ET-1).
Data have emerged that endothelial dysfunction
is an early step in developing atherosclerosis and
is  characterized  mainly  by  a reduction  in  the
bioavailability of NO [10]. Endothelial function is
often quantified by FMD, which represents the
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endothelium-dependent  vasorelaxation  of  the
brachial artery, owing to increased blood flow [7,
11]. We showed the validity of the measurement of
endothelial dysfunction using the FMD approach in
a selected group of normolipidaemic, treated hyper-
tensive patients.
Because endothelial dysfunction plays a signif-
icant role in the pathogenesis of arterial hyperten-
sion, it is reasonable to search for new strategies
aimed at improving endothelial function [12]. Sev-
eral studies indicate that statins could influence
blood pressure control in various hypertensive
8
6
4
2
0
–2
–4
–6
–8
–10
–12
A A B B
3 3   m mo on nt th hs s, ,   b be ef fo or re e   c cr ro os ss so ov ve er r
p = 0.22
p = 0.27
B
B
P
P
 
 
c
c
h
h
a
a
n
n
g
g
e
e
s
s
 
 
[
[
m
m
m
m
H
H
g
g
]
]
F Fi ig gu ur re e   3 3. .   Changes in SBP and DBP values in patients with FMD improvement (ANOVA test)
SBP – systolic blood pressure, DBP – diastolic blood pressure, FMD – flow-mediated dilation
SBP         DBP
25
20
15
10
5
0
–5
–10
–15
A A* * B B* *
6 6   m mo on nt th hs s, ,   b be ef fo or re e   c cr ro os ss so ov ve er r
p = 0.04
p = 0.03
B
B
P
P
 
 
c
c
h
h
a
a
n
n
g
g
e
e
s
s
 
 
[
[
m
m
m
m
H
H
g
g
]
]
SBP         DBP
0.20
0.18
0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0
T TA AS S
3 3   m mo on nt th hs s, ,   b be ef fo or re e   c cr ro os ss so ov ve er r
p = NS
T
T
A
A
S
S
 
 
c
c
h
h
a
a
n
n
g
g
e
e
s
s
 
 
[
[
m
m
m
m
o
o
l
l
/
/
l
l
]
]
150
100
50
0
–50
–100
–150
–200
O Ox xy ys st ta at t
3 3   m mo on nt th hs s, ,   b be ef fo or re e   c cr ro os ss so ov ve er r
p = NS
O
O
x
x
y
y
s
s
t
t
a
a
t
t
 
 
c
c
h
h
a
a
n
n
g
g
e
e
s
s
 
 
[
[
µ
µ
m
m
o
o
l
l
/
/
l
l
]
]
F Fi ig gu ur re e   4 4. .   FMD changes in relation to TAS and Oxystat concentrations in group A patients (all p = NS)
FMD – flow-mediated dilation, TAS – total antioxidant status, Oxystat – a method to measure peroxide concentrations
FMD decrease         FMD increase FMD decrease         FMD increase
1.00
0.80
0.60
0.40
0.20
0
–0.20
–0.40
–0.60
E ET T- -1 1
6 6   m mo on nt th hs s, ,   a af ft te er r   c cr ro os ss so ov ve er r
p = NS
E
E
T
T
-
-
1
1
 
 
c
c
h
h
a
a
n
n
g
g
e
e
s
s
 
 
[
[
f
f
m
m
o
o
l
l
/
/
m
m
l
l
]
]
20
10
0
–10
–20
–30
–40
–50
N NO O
6 6   m mo on nt th hs s, ,   a af ft te er r   c cr ro os ss so ov ve er r
p = NS
N
N
O
O
 
 
c
c
h
h
a
a
n
n
g
g
e
e
s
s
 
 
[
[
I
I
U
U
/
/
l
l
]
]
F Fi ig gu ur re e   5 5. . FMD changes in relation to NO and ET-1 concentrations in group B* patients (all p = NS)
FMD – flow-mediated dilation, NO – nitric oxide, ET-1 – endothelin-1
FMD decrease         FMD increase FMD decrease         FMD increase960 Arch Med Sci 6, December / 2011
A.M. Tycinska, J. Janica, B. Mroczko, W.J. Musial, R. Sawicki, B. Sobkowicz, K. Kaminski, U. Lebkowska, M. Szmitkowski
patients [5]. This is a pleiotropic statin effect, i.e.
independent of lipid-lowering [13]. 
Still, the hypotensive effect of statin seems to
be ambiguous [13]. Koh et al. in their review article
interpret various animal and clinical studies regard-
ing the blood pressure lowering statin effect. The
variety of results could be related to various blood
pressure measurement techniques and various
statins used, small sample size study populations,
confounding effects of concomitant anti-hyperten-
sive therapy, various criteria, different comparative
groups and, finally, various populations studied. It
has been observed that statins lower blood pres-
sure values in patients with elevated, but not nor-
mal blood pressure regardless of cholesterol level
[13]. These results have been confirmed by Borghi
et al. in the Brisighella Heart Study – a large ran-
domized controlled trial [14]. Among 1356 patients
with hypercholesterolaemia, a significant decrease
in blood pressure was observed in the two upper
quartiles of systolic blood pressure (≥ 140 mmHg)
and was greater in patients treated with statins.
Thus, it has been suggested that statins significantly
lower blood pressure in patients with uncontrolled
hypertension, but not in patients with controlled
hypertension or normotension [13]. Moreover, in the
CAFE-LLA (The Conduit Artery Function Evaluation-
Lipid-Lowering Arm) – a substudy of an Anglo-Scan-
dinavian Cardiac Outcomes Trial (ASCOT) – 891
patients with hypertension were randomized to
atorvastatin 10 mg daily or placebo. Statin therapy
did not influence central aortic blood pressure or
haemodynamics [15]. The results of PHYLLIS (Plaque
Hypertension Lipid-Lowering Italian Study) – a ran-
domized double blind trial – confirmed that the addi-
tion of pravastatin to anti-hypertensive treatment
did not cause a reduction in systolic and diastolic
blood pressure values in patients with low blood
pressure at baseline (clinic systolic 160 mmHg, 
24-h systolic 137 mmHg; clinic diastolic 98 mmHg
and 24-h diastolic 85 mmHg) [16].
However, in the previous study, we confirmed
the hypotensive effect of atorvastatin in normolip-
idaemic patients with already treated and well-con-
trolled essential arterial hypertension. What is more,
we investigated the influence of statin therapy on
various biomarkers which are involved in the patho-
genesis of essential arterial hypertension [6]. We
discovered  that  in  statin-treated  patients  the
decrease in blood pressure was correlated with the
increase in NO and the decrease in autoantibodies
against oxidized LDL (ox-LDL). 
In the current study, we aimed to investigate the
influence of statin treatment on FMD and intend-
ed to assess what the blood pressure would be
after stopping atorvastatin therapy. A high dose of
atorvastatin decreased blood pressure values and
a greater reduction was concurrent with FMD
improvement. Conversely, after suspending statin
therapy, systolic blood pressure values significant-
ly  increased,  which  was  consistent  with  FMD
impairment. Bellia and associates showed that sim-
vastatin significantly improved FMD to a greater
extent than rosuvastatin. However, no association
between FMD improvement, low-density lipopro-
tein cholesterol (LDL) reduction, and changes in
high-sensitivity C-reactive protein (hs-CRP) levels
were found [17]. In our study, we assessed bio-
markers of oxidative stress, antioxidative status
and endothelial dysfunction, and failed to demon-
strate significant relations between them and FMD
variation. Based on recent data, we presumed to
intensify the investigations. We wanted to find the
link between the hypotensive effect of statin, FMD
improvement, and changes in concentrations of bio-
markers in essential hypertensive patients.
A reduction of NO and an increase in ET-1 secre-
tions have been observed in hypertensive patients
[2, 18]. Moreover, several diseases, including hyper-
tension, have been proved to be related to oxida-
tive stress and production of free radicals. It has
been suggested that high blood pressure is a state
associated with a loss of the balance between pro-
oxidation and antioxidation [3]. Increased levels of
peroxides and decreases in antioxidants in patients
with essential arterial hypertension have been
reported earlier [18]. However, to our knowledge,
changes in these agents in the aspect of FMD
improvement or impairment after statin therapy
have  not  been  investigated  previously.  In  our
patients, FMD improvement was related to a trend
towards increase in total antioxidant status, which
was less evident, but still present, after the with-
drawal of statin therapy (in patients with FMD
impairment). This may suggest a lasting antioxi-
dant statin effect.
Simultaneously, FMD improvement was related
to the decrease in peroxide concentration (mea-
sured by Oxystat) and FMD impairment was relat-
ed to its increase. In the same way, NO and ET-1
concentration changes were observed: vasodilata-
tive NO tended to increase and vasoconstrictive 
ET-1 to decrease after statin therapy, and these
effects were consistent with FMD improvement. 
We chose a selected group of treated, nor-
molipidaemic patients and added to that treatment
a high dose of atorvastatin. There are some data
proving that a low dose of atorvastatin could have
pleiotropic effects. Kuryata and Yegorova demon-
strated an improvement in endothelial function
assessed by FMD in patients with coronary artery
disease treated with atorvastatin 10 mg daily for 
12 weeks [19]. Administration of a statin in hyper-
tensive patients with blood pressure values effec-
tively  reduced  by  traditional  anti-hypertensive
agents does not have an additional blood pressureArch Med Sci 6, December / 2011 961
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lowering effect [13]. Thus, we wanted to use a high-
er dose of atorvastatin to have a better potential
effect in treated hypertensives. 
Some studies found no change in blood pressure
levels with additional statin treatment in patients
with controlled hypertension by angiotensin-con-
verting enzyme inhibitors and calcium antagonists
or atenolol. The addition of simvastatin to losartan
did not enhance the blood pressure lowering action
of losartan in hypertensive and hypercholestero-
laemic patients [20]. The antihypertensive effect of
captopril and atenolol was not influenced by con-
current administration of pravastatin [21]. In hyper-
tensive, hypercholesterolaemic patients, pravas-
tatin remains efficacious as a lipid-lowering agent
in  the  presence  of  antihypertensive  therapy
(angiotensin-converting enzyme inhibitors and cal-
cium antagonists), but does not enhance the blood
pressure lowering action of these drugs [22]. How-
ever, the results of one study demonstrate that the
use of statins in combination with anti-hyperten-
sive drugs can improve blood pressure control in
patients with uncontrolled hypertension and high
serum cholesterol levels [23]. The changes in blood
pressure values in our studied hypertensive patients
with previous optimal anti-hypertensive treatment
and with a normal lipid profile after 3 months 
of  high-dose  atorvastatin  treatment  could  be
explained by such a synergy with other drugs. 
Ge et al. have shown that atorvastatin added to
amlodipine, apart from inhibition of the inflamma-
tory process and reduction of left ventricular hyper-
trophy, markedly decreased systolic and diastolic
blood pressure values as compared to amlodipine
alone [24]. 
Our hypertensive patients, besides well-con-
trolled diseases, were normolipidaemic. In the pre-
vious report, we revealed that the hypotensive
effect of atorvastatin in properly treated patients
is  independent  of  lipid-lowering  [6].  To  avoid
methodological limitations, a selected group of
homogeneous patients was studied. The study was
prospective, randomised and had a cross-over
design. To assume that both groups of patients
received a comparable proportion of anti-hyper-
tensive agents, group B was created to prove the
potential hypotensive effect of atorvastatin in group
A. Also, in contrast to previous studies, we used
ABPM. Available data are largely limited to blood
pressure values measured in the clinic without pro-
viding information on ambulatory blood pressure,
which is of greater prognostic importance [25-27].
Finally, we examined young hypertensive patients,
and available data provide information that, at least
in patients with metabolic syndrome, FMD changes
were observed in the elderly [28].
In conclusion, the present data demonstrate that
the hypotensive effect of atorvastatin is related to
FMD improvement in normolipidaemic hyperten-
sive patients with previously diagnosed and treat-
ed disease. Thus, there may be a link between ator-
vastatin action and improvement in endothelial
function.
The main limitation of this study is the small
number of patients. This might be the reason for
trends – not significant changes – in some of the
parameters assessed. However, there are studies
assuming the same issue, but investigating even
smaller groups of patients [29]. Since higher base-
line systolic and diastolic blood pressure values
could also influence the results, it is hard to com-
pare these studies. Patients with high blood pres-
sure levels at baseline as well as those treated with
angiotensin-converting enzyme inhibitors and cal-
cium channel blockers are expected to benefit more
in this regard [30]. Furthermore, the differences in
baseline levels of peroxides, endothelin and NO
between the two groups were quite big; this could
have also influenced the results. Perhaps it would
be more interesting to compare different doses of
the same statin, or different statins (particularly
those commonly used – simvastatin, atorvastatin
and rosuvastatin). However, our study sought to
examine a selected group of hypertensive patients.
Moreover, we used a prospective cross-over design
to increase the statistical power of the study. Treat-
ment with statins during the studies that reported
blood pressure data ranged from 1 to 12 months.
A short time of statin treatment could probably
influence biochemical results. However, the patients
were followed prospectively and were investigated
thoroughly; therefore, the authors consider the
obtained results as being representative.
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